The brochure describes that the liposome is an ideal drug delivery carrier with characteristic lipid bilayers that resemble the cell plasma membrane and high biosecurity. They can incorporate a variety of drug candidates including anti-cancer formulations, nucleic acid and antigens. Liposomes are the most widely used carriers for delivering CRISPR/Cas9 due to their capacity to extend blood circulation time and prevent the enzymatic digestion in the serum. Besides, cationic liposomes can effectively avoid the electrostatic repulsion of negatively charged cell membranes and improve cellular uptake and endosomal escape. Different structures of liposomes such as lipoplexes, stable nucleic-acid-lipid particles (SNALPs), lipopolyplexes, and membrane/core nanoparticles (MCNPs) can provide encapsulation of CRISPR/Cas9 plasmid, Cas9 mRNA with sgRNA or Cas9–gRNA ribonucleoprotein. The flexibility of liposomes also allows the many parameters to be adjusted as needed, including the degree of PEGylation, targeting ligands, and surface charge.

Content

1. Background
2. CRISPR/Cas9
3. Liposomal Delivery of CRISPR/Cas9
4. Liposome Surface Modifications
5. Recent Studies on Liposomal Delivery of CRISPR/Cas9